Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment.
J Clin Pharm Ther
; 46(5): 1465-1468, 2021 Oct.
Article
en En
| MEDLINE
| ID: mdl-33534133
WHAT IS KNOWN AND OBJECTIVE: Drug-drug interactions can involve inhibition or induction of cell membrane transporters. Deinduction occurs after an inducing agent is stopped. CASE SUMMARY: This case describes suspected P-glycoprotein (P-gp) deinduction by carbamazepine resulting in a slow viral response during treatment of chronic hepatitis C virus (HCV) infection. Evidence of deinduction occurred beyond clearance of carbamazepine and resulted in extension of HCV treatment. WHAT IS NEW: The understanding of the role P-gp transport plays in drug elimination is relatively new and evidence of P-gp deinduction is variable. CONCLUSION: Clinicians should consider deinduction when starting and stopping medications involving strong inducers of P-gp transport proteins.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Ribavirina
/
Carbamatos
/
Carbamazepina
/
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP
/
Hepatitis C Crónica
/
Antirretrovirales
/
Sofosbuvir
/
Compuestos Heterocíclicos de 4 o más Anillos
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Clin Pharm Ther
Asunto de la revista:
FARMACIA
/
TERAPEUTICA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos